Mutations in distant regulatory elements can negatively impact human development and health, yet due to the difficulty of detecting these critical sequences we predominantly focus on coding sequences for diagnostic purposes. We have undertaken a comparative sequence-based approach to characterize a large noncoding region deleted in patients affected by Van Buchem disease (VB), a severe sclerosing bone dysplasia. Using BAC recombination and transgenesis we characterized the expression of human sclerostin (sost) from normal (hSOST wt ) or Van Buchem (hSOST vb∆ ) alleles. Only the hSOST wt allele faithfully expressed high levels of human sost in the adult bone and impacted bone metabolism, consistent with the model that the VB noncoding deletion removes a sostspecific regulatory element. By exploiting cross-species sequence comparisons with in vitro and in vivo enhancer assays we were able to identify a candidate enhancer element that drives human sost expression in osteoblast-like cell lines in vitro and in the skeletal anlage of the E14.5 mouse embryo, and discovered a novel function for sclerostin during limb development. Our approach represents a framework for characterizing distant regulatory elements associated with abnormal human phenotypes.
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Deleterious mutations in distant regulatory elements postulated to dramatically impact human development and health have been minimally explored. This problem is in large part due to the fact that there are no simple ways to discern regulatory elements from nonfunctional sequences or to ascertain whether mutant phenotypes are caused by regulatory mutations. Among Mendelian disorders associated with noncoding mutations only a few cases are described that clearly link alterations in distant cis-acting regulatory regions to the cause of the disease (Enattah et al. 2002; Ionasescu et al. 1996 ; Lettice et al. 2003; Tsui et al. 2003; Wang et al. 2000) , and these documented cases predominantly correspond to large chromosomal aberrations (Chuzhanova et al. 2003; Cimbora et al. 2000; Curtin et al. 1985; Curtin and Kan 1988; Kleinjan et al. 2001) . Structural variation in the human genome described as large-scale polymorphisms has been recently shown to be more common than previously anticipated (Sebat et al. 2004 ), therefore the extend to which large noncoding duplications and deletions impact human biology remains a largely unanswered question. In this study, we demonstrate that a very important skeletal dysplasia, Van Buchem (VB) disease, associated with a large noncoding deletion is caused by the removal of a bone-specific distant enhancer element.
Van Buchem disease (MIM 239100) is a homozygous recessive disorder (Balemans et al. 2002; Staehling-Hampton et al. 2002; Van Hul et al. 1998 ) that maps to chromosome 17p21 and results in progressive increase in bone density (Wergedal et al. 2003 ). The accumulation of bone mass gives rise to facial distortions, enlargement of the mandible and head, entrapment of the cranial nerves, increase in bone strength, and excessive weight (Balemans et al. 2002; Staehling-Hampton et al. 2002; Van Hul et al. 1998 ). Sclerosteosis (MIM 269500) is a cranio-tubular hyperosteosis that is 5 phenotypically indistinguishable from Van Buchem disease (VB) except that it is more severe and occasionally displays syndactyly of the digits (Balemans et al. 1999; Beighton et al. 1977; Brunkow et al. 2001; Hamersma et al. 2003; Kusu et al. 2003) , a trait absent in VB patients.
An exciting development has been the recent discovery of a novel protein that acts as a negative regulator of bone formation, sclerostin (SOST) (Balemans et al. 2001; Brunkow et al. 2001) , whose expression is affected in both sclerosteosis and Van Buchem disease. Whereas sclerosteosis patients carry homozygous null sost mutations, VB patients lack any sost coding mutations (Staehling-Hampton et al. 2002; Van Bezooijen et al. 2004; Winkler et al. 2003) . They do however, carry a homozygous 52 kb noncoding deletion (vb∆) ~35kb downstream of the sost transcript and ~10kb upstream of the downstream gene, meox1, on human chromosome 17p21 ( Figure 1A ) (Balemans et al. 2002; Staehling-Hampton et al. 2002) . The shared clinical similarities between VB and sclerosteosis along with their strong genetic linkage to the sost locus on chromosome 17q12 suggests that they are allelic, and that the deletion in VB patients removes an enhancer element essential for directing the expression of human sost in the adult skeleton. To gain insight into the mechanism by which this newly discovered gene by the removal of bone-specific distant enhancer elements and is allelic to sclerosteosis.
Results

Molecular and Phenotypic Characterization of Van Buchem transgenic mouse models
A ~158 kb human BAC (RP11-209M4) (hSOST wt ) encompassing the 3'end of the DUSP3 gene, sost, meox1, and the ~90kb noncoding intergenic interval separating sost from the neighboring gene, meox1, was engineered using homologous recombination in bacteria (Lee et al. 2001) to delete the 52kb region missing in VB patients and to create a construct that mimics the VB (hSOST vb∆ ) allele ( Figure 1A ). Three independent founder lines of each transgenic construct were generated using standard transgenic procedures (Nobrega et al. 2003) . Similar to the endogenous mouse sost expression, and the reported human expression (Balemans et al. 2001; Brunkow et al. 2001) ) also consistently expressed human sost in the adult kidney and heart. Here, we present data on the top expressing lines from each transgenic construct, which are referred to in the manuscript as A and B version of each transgene ( Figure 1B) . Expression in the lung, brain and spleen varied among lines, while no BAC transgenic line expressed in the liver contrary to the reported human tissue-specific expression (Brunkow et al. 2001 ). These data demonstrate that in vivo, the VB allele confers dramatically reduced sost expression in the adult bone and suggests that the vb∆ contains essential bone-specific enhancer elements.
Sclerostin is an osteocyte-expressed negative regulator of bone formation that is structurally most closely related to the DAN/Cerberus family of BMP antagonists (Van 8 Bezooijen et al. 2004; Winkler et al. 2003) . Several members of this family including noggin and gremlin are expressed embryonically in the developing limb (Brunet et al. 1998; Khokha et al. 2003 ), therefore we examined human sost expression in the early mouse embryo. rtPCR analysis of RNA isolated from whole embryos showed high levels of human sost expression in all lines from both hSOST wt and hSOST vb∆ transgenic animals ( Figure 1C ). Sost expression precedes endochondral ossification, and was detected as early as E9.5. Since the VB deletion did not impact human sost embryonic expression, we used E10.5 embryonic RNA to quantify the level of transgene expression in different hSOST wt and hSOST vb∆ transgenic founder lines ( Figure 1D ). Comparable expression levels were also confirmed in the kidneys of hSOST wt and hSOST vb∆ animals.
This data strengthens the evidence that the lack of human sost bone expression in hSOST vb∆ animals is dependent on the 52kb noncoding deletion, rather than reflecting an artifact due to transgene copy number or site of integration.
The availability of BAC transgenic animals carrying wildtype and VB alleles also allowed us to address whether the other gene flanking the vb∆ region, the transcription factor meox1 is affected by removing the 52kb vb∆. Meox1 has been previously shown to be involved in skeletal myogenesis (Mankoo et al. 2003; Petropoulos et al. 2004) , therefore it has been uncertain whether it also plays a role in the phenotypic outcomes of Van Buchem Disease, particularly since previous experiments using human patient samples prevented researchers from directly examining the effect of the noncoding deletion on gene expression (Staehling-Hampton et al. 2002 Interestingly, and consistent with the observed embryonic expression, elevated levels of human sost result in abnormal digit development in both hSOST wt and hSOST vb∆ BAC transgenics bred to homozygosity. The fore-and hind-limbs of these animals display a wide range of fused and missing digits as visualized by autoradiography (data not shown) and µCT ( Figure 4B ). rtPCR data correlates SOST expression with the severity of digit abnormalities (data not shown). Mouse whole mount in situ hybridization revealed sost to be expressed as early as embryonic stage 9.5 (E9.5), predominantly in the mesenchymal tissue of the developing limb bud ( Figure 4A ). These findings imply that sost embryonic expression is controlled by a transcriptional regulatory element different from the one driving the adult bone expression, consistent with the observation that both sclerosteosis and VB patients suffer from abnormal bone mass accumulation while only sclerosteosis patients exhibit syndactyly of the digits (Staehling-Hampton et al. 2002) .
Comparative Sequence Analysis and Enhancer Assays
Given the striking bone phenotypes observed in both VB and sclerosteosis patients, we next focused on the identification of noncoding sequences required for sost bone-specific expression through a combination of comparative sequence analysis and transient transfection assays. We aligned a ~140kb human SOST region were prioritized for in vitro enhancer analysis. ECR2-8 were tested for their ability to stimulate a heterologous promoter (SV40) in osteoblastic (UMR-106) and kidney (293) derived cell lines. One element, ECR5, was able to stimulate transcription in UMR106 cells ( Figure 5B ), but not in the kidney cell line, suggesting that ECR5 enhancer function is specific to the osteoblastic lineage. We also tested the transcriptional activity of the human sost proximal promoter region (2kb region upstream of 5'UTR) in the two cell types and compared it to the SV40 and the osteoblast-specific osteocalcin promoter (OG2). The SV40 promoter showed comparable activity in both cell lines and, as expected, OG2 was only active in the UMR-106 cells. The human sost promoter stimulated transcription in the osteoblastic cells similarly albeit slightly higher activity than the OG2 promoter, while it demonstrated a threefold stronger activity in kidney cells ( Figure 5B ). These data suggest that sost kidney expression may be due to proximal promoter sequences, whereas strong expression in osteoblast cells requires the activity of the ECR5 element. Consistent with the results obtained from transfecting SV40 promoter constructs, only ECR5 was capable of activating the human sost promoter (4X) in UMR106 cells ( Figure 5C ), while all other ECR-constructs had background level expression. Thus, a small sequence element within the vb∆ region (ECR5) was identified that confers in vitro osteoblast-specific enhancer activity onto both the human sost and the SV40 heterologous promoter.
To test ECR5's ability to drive expression in the skeletal structures of the mouse embryo we expressed a ECR-hsp68-LacZ construct in transgenic mice ( Figure 5D ) (Nobrega et al. 2003) . Transient transgenic animals were created using standard techniques (Mortlock et al. 2003 ) and F0 pups were stained for β-galactosidase expression at E14.5 (Nobrega et al. 2003) . Transgenic embryos expressed LacZ in the cartilage of the ribs, vertebrae and skull plates ( Figure 5D ) and the expression was identical in all positive transgenic embryos obtained from two independent injections (N=2). In parallel we also injected ECR4-and ECR6-hsp68-LacZ constructs and assayed
LacZ expression at E12.5 and E14.5. None of the ECR4 (N=6) and ECR6 (N=2) positive embryos expressed LacZ at these time points. These data highly suggest that the 250 basepair (bp) ECR5 element contained within the 52 kb deleted in Van Buchem patients functions to drive sost bone-specific expression in vivo.
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Discussion
Sclerosing bone dysplasias are rare genetic disorders in which excessive bone formation occurs due to defects in bone remodeling . Identifying the responsible genes, their regulation and mechanisms of action will provide useful insights into bone physiology and potentially benefit the treatment of these disorders, as well as facilitate the development of therapies for replenishing bone loss in osteoporosis. In this study we have demonstrated that the 52 kb noncoding deletion present in Van Buchem patients removes a distant sost-specific regulatory element and therefore Van Buchem disease is hypomorphic to sclerosteosis. Currently, we don't have a clear view of how the lack of sclerostin promotes osteogenesis, therefore elucidating its transcriptional regulation is key to understanding the interconnection between its expression pattern in osteogenic cells and its mode of action either as a BMP-antagonist (Winkler et al. 2003) or WNT-antagonist. The elaborate expression pattern we detect along with the multitude of putative enhancer elements that have the potential to positively or negatively impact sost in a spatial and temporal precise manner attest to this molecule's complexity and functional versatility. Consistent with this view, our analysis provides robust in vivo evidence for the role of sclerostin during bone formation, modulation of adult bone mass and for a novel function during limb development.
In general, the osteopenic phenotype we observed is consistent with reports describing transgenic mice overexpressing BMP-antagonists from cDNA constructs driven by osteocalcin (OG2) promoter (Devlin et al. 2003; Winkler et al. 2003) . Unlike Since sclerosteosis is caused by sost null mutations (Balemans et al. 2001; Brunkow et al. 2001) , our results indicate that VB disease and sclerosteosis are allelic, VB patients are hypomorphic for the sost gene and lack sost expression in the adult bone.
Our data suggests that sost embryonic expression is unaltered in VB patients, who also never display syndactyly of the digits, indicating that both reduced and elevated levels of human sclerostin negatively impact limb development and digit formation, a novel function attributed to this molecule.
Our findings provide evidence that noncoding regions in the VB deletion control
Sclerostin expression levels and modulate BMD in mice, therefore an important question is whether variation in BMD in the general population could also be directly impacted by sequence variants in key noncoding regions of the VB deletion. A recent new study investigated the association between common polymorphisms in the sost gene region with BMD in elderly whites (Uitterlinden et al. 2004) . From a set of 8 polymorphisms, one 3-bp deletion (SRP3) from the sost promoter region was associated with decreased BMD in women, and a polymorphic variant (SRP9) from the VB deletion region was associated with increased BMD in men. Whereas this SRP9 does not map on any humanmouse conserved region in the VB deletion, an important question for future studies is whether this SNP is in linkage disequilibrium with ECR5 or if additional functional SNPs could be identified in this or other sost-specific enhancer elements.
The genetic factors that contribute to susceptibility to bone loss are extremely heterogeneous, therefore murine models that affect bone development and growth can provide invaluable insights into the molecular mechanisms of progressive bone loss in humans. Human genetic diseases of the skeleton such as sclerosteosis and Van Buchem disease provide a starting point for understanding the modulation of anabolic bone formation, and ultimately have the potential to identify key molecular components that can be used as new therapeutic agents to treat individuals suffering from bone loss disorders. Our study also provides strong support for the utilization of comparative sequence analysis to dramatically filter through nonfunctional regions in the human genome and enhance the discovery of noncoding disease-causing mutations both in discrete enhancer elements or in large noncoding deletions. This study represents a clear and unambiguous case where altering noncoding genomic content deleteriously impacts gene expression, demonstrating that mutations in distant regulatory elements are able to cause congenital abnormalities analogous to coding mutations.
Methods
Generating Transgenic Mice
FRT-kan-FRT cassette was excised from pICGN21 vector (KpnI; SacI) and inserted into pUC18 to create pUC18.kan. Recombinant BACs were identified by PCR and pulse-field gel analysis, were isolated at a final concentration of 1 ng/ml and microinjected into fertilized FVB mouse eggs using standard procedures. Transgenic mice were genotyped using PCR analysis of DNA prepared from tail DNA of founder animals using the following primer pair: 5' -ATGTCCACCTTGCTGGACTC-3' and 5' -GTCTGTGGGCTGGTTTGCAT-3' .
Transgenic mice were maintained on FVB background.
RT-PCR, Quantitative RT-PCR and in situ hybridization
Total RNA was isolated with Trizol reagent (Invitrogen) and reverse-transcribed into cDNA (Superscript II, Gibco) using standard methods. cDNA was amplified using GC- TaqMan® assay reagent for normalization and TaqMan® Assay-on-Demand™ products for mouse, rat and human SOST all from Applied Biosystems. We considered noon on the day that we found a vaginal plug to be E0.5. We carried out RNA localization by whole-mount in situ hybridization according to established protocols. RNA antisense probes were labeled with digoxigenin and were synthesized with T7 RNA polymerase as previously described.
Dual energy X-ray absoptiometry (DEXA) analysis.
Tibial, femoral and lumbar vertebral bone mineral density (in milligrams per square centimeter) was measured using a regular Hologic QDR-1000 instrument (Hologic, Waltham, Mass., USA). A collimator with 0.9-cm-diameter aperture and an ultrahigh resolution mode (line spacing, 0.0254 cm; resolution, 0.0127 cm) were used. The excised long bones were placed in 70% alcohol onto a resin platform provided by the company for soft tissue calibration. Daily scanning of a phantom image controlled the stability of the measurements. Instrument precision and reproducibility had been previously evaluated by calculating the coefficient of variation of repeated DEXA and had been found to be below 2%. Coefficients of variation were 0.5 to 2% for all evaluated parameters. A set of 5-month-old male mice was analyzed (non-tg = 13 littermates of all analyzed lines, hSOST wt = 15 (heterozygous mice from 2 hSOST wt BAC lines, hSOST vb∆ = 14 off-springs of heterozygous matings from 2 hSOST vb∆ lines).
Micro computed tomography (microCT) analysis.
Cancellous bone structure was evaluated in the proximal tibia metaphysis using a Scanco vivaCT20 (Scanco Medical AG, Bassersdorf, Switzerland). The nonisometric voxels had a dimension of 12.5µm x 12.5µm x 12.5µm. From the cross-sectional images the cancellous bone compartment was delineated from cortical bone by tracing its contour at every 10th section. In all the other slices boundaries were interpolated based on the tracing to define the volume of interest. 660 slices covering a total length of 0.8mm within the area of the secondary spongiosa (1.3mm from the proximal end) were evaluated. A threshold value of 175 was used for the three dimensional evaluation of trabecular number, thickness, and separation. Both sets of male 5-month-old mice on which DEXA and histomorphometric analysis has been performed were analyzed. A voxel size of 25µm x 25µm x 25µm was chosen for visualization of the digits of the foreand hind limbs.
Histomorphphometric analysis.
After dissection, the tibia and lumbar vertebrae were placed for 24h in Karnovsky' s fix, dehydrated in ethanol at 4°C, and embedded in methylmethacrylate. A set of 4-and 8-, microm-thick nonconsecutive microtome sections were cut in the frontal midbody plane for evaluation of fluorochrome-label-based dynamic and cellular parameters of bone turnover. The 4 microm-thick sections were stained with TRAP and Giemsa stain. The sections were examined using a Leica DM microscope (Leica, Glattbrugg, Switzerland) fitted with a camera (SONY DXC-950P, Tokyo, Japan) and adapted Quantimet 600 software (Leica, Cambridge, UK). Two sections/animal were sampled for all sets of parameters. Microscopic images of specimens were evaluated semiautomatically digitally (X400 magnification). All parameters were measured and calculated according to Paritt 
In vitro Enhancer Assays
ECRs were PCR-amplified with 5' NheI-linkers, TOPO-cloned into pCR2.1 vector Fournier (Novartis Basel, Switzerland) . Reporter plasmids containing ECR-4, -5 or -6
upstream of the human sost promoter were generated by inserting the ECR elements into the NheI site. Plasmid DNA was isolated using standard endotoxin-free methods (Qiagen). FuGene (Roche) and a CMV-bgal reporter plasmid (Clontech) as internal control were used for transient transfections of rat UMR-106 and human 293 cells. Cells were incubated for 24 hours at 37ºC and luciferase and galactosidase expression were measured using standard assay kits (Promega).
Transient transgenic analysis
500 mg of DNA was linearized with NotI, followed by CsCl gradient purification and 2-5 ng was used for pronuclear injections of FVB embryos. E12.5-E14.5 embryos were dissected in ice-cold PBS, and were fixed in 4% paraformaldehyde at 4ºC for 1-2 hours and stained for LacZ as described. 
